Class Action Lawsuit Filed Against ImmunityBio, Claiming Securities Fraud Involving Anktiva

Overview of ImmunityBio's Recent Legal Issues

ImmunityBio, Inc. (NASDAQ: IBRX) is currently facing a significant legal challenge, as a securities fraud class action lawsuit has been filed against the company. This arises from claims that ImmunityBio made materially false representations about its lead biologic product, Anktiva, between January 19, 2026, and March 24, 2026. Investors who acquired IBRX securities during this period are being notified and encouraged to pay attention to the unfolding situation.

What Happened?

According to the complaint attributed to Kessler Topaz Meltzer & Check, LLP, this lawsuit aims to offer relief to IBRX investors who believe they were misled by ImmunityBio’s statements about Anktiva. The key allegations indicate that the company made several misrepresentations regarding the efficacy and potential of Anktiva, particularly its classification as a cancer vaccine. It is claimed that the Executive Chairman and Global Scientific and Medical Officer glorified the product's capabilities, which have now been called into serious question.

Key Allegations in the Lawsuit

The lawsuit emphasizes three major allegations:
1. False Claims: Asserted that ImmunityBio misrepresented Anktiva as a cancer vaccine without substantiating evidence.
2. Overstated Capabilities: Statements made by leadership about Anktiva's potential to cure or prevent cancer were exaggerated.
3. Market Impact: These misleading statements caused significant drops in the company's stock price, notably after the FDA issued a warning regarding the inaccuracy of promotional statements made about Anktiva on public forums.

Stock Market Reaction

The impact of these revelations on ImmunityBio’s stock was immediate and severe. Following the FDA’s public repudiation of the company's claims on March 24, 2026, the stock plummeted by 21.12%, closing at approximately $7.42. This dip reflects investor concerns over the reliability of ImmunityBio’s communications about Anktiva, further compounded by legal uncertainties now surrounding the firm.

Next Steps for Investors

Investors who bought ImmunityBio shares during this timeframe are encouraged to evaluate their options, especially regarding the opportunity to participate as lead plaintiffs in the class action suit. The deadline to seek such status is set for May 26, 2026. Interested parties should reach out to Kessler Topaz Meltzer & Check, LLP, who can provide insights into potential recovery options.

Contacting the Law Firm

KTMC initially alerted the public about this lawsuit, and they are available for consultations at no upfront cost. Investors can communicate with attorney Jonathan Naji at (484) 270-1453 or visit their website for more information. This communication may not only provide clarity on the investor's rights but also details on the possible outcomes of the ongoing legal proceedings.

Conclusion

The securities fraud class action lawsuit against ImmunityBio marks a critical juncture for the company and its investors. With substantial claims being made regarding misleading statements, the ramifications for the biotech firm could be profound. Investors are urged to remain vigilant and informed about these developments in order to safeguard their interests in light of the evolving legal landscape surrounding ImmunityBio, Inc.